Eli Lilly

Eli Lilly is suing six companies over alleged illegal sales concerning its unapproved weight loss drug. The article clarifies that this drug remains in Phase 3 clinical trials and has not been approved by any regulator for human use.

The U.K. regulator has approved orforglipron for weight management and type 2 diabetes. This approval makes Britain the first country in Europe to clear the drug.

Eli Lilly's drug, Foundayo, has won approval in the U.K., extending its participation in the weight-loss pill battle beyond the U.S. market. This development intensifies the competition between Eli Lilly and Novo Nordisk regarding their respective treatments.

Danish company Novo Nordisk developed a highly lucrative GLP-1 weight-loss drug but lost market dominance to American rival Eli Lilly. The article questions Europe's ability to compete in the global economy as Eli Lilly outmaneuvered Novo Nordisk in the diet-drug market.

AMD and SpaceX are experiencing stock price declines following their earnings reports, while Eli Lilly's stock is rising after it significantly exceeded earnings estimates.

Eli Lilly and Novo Nordisk raised their profit outlooks due to increased demand for weight-loss drugs. Investors are showing a dim view of Novo Nordisk's over-reliance on obesity treatments, causing diverging share prices between the two drugmakers.

Eli Lilly reported higher-than-expected earnings as revenue from its weight loss drugs Mounjaro and Zepbound surged, with Mounjaro revenue rising 91% to $9.9 billion and Zepbound generating $4.9 billion.

CVS Health's profit nearly tripled in the second quarter, beating Wall Street expectations. The company raised its full-year profit forecast to as much as $8.10 per share due to a weight loss drug deal with Eli Lilly.

Eli Lilly reported quarterly results that exceeded expectations, leading to an upward revision of its 2026 revenue forecast. The company now anticipates revenue between $85 billion and $87 billion for 2026, driven by strong sales of Zepbound and Mounjaro.

CVS exceeded estimates and raised guidance due to improvements in its insurance unit. The company announced a collaboration with Eli Lilly to make Zepbound and Foundayo accessible to eligible patients via the CVS Health app.

Novo Nordisk raised its forecast for its obesity business, but Wall Street remains unconvinced about its ability to achieve sustainable growth amid intensifying competition from Eli Lilly.

Eli Lilly is allowing more patients early access to its experimental weight loss drug. The company will review requests from doctors for patients who cannot enroll in clinical trials.

Eli Lilly will allow other patients to apply for early access to its experimental obesity drug retatrutide, expanding on a prior decision to grant access to a single 79-year-old patient. The company plans to review applications for special access to the next-gen therapy.

Eli Lilly is allowing patients to apply for early access to retatrutide, an unapproved obesity drug, following a special access request for a 79-year-old patient. The California Supreme Court ruled in favor of Gilead Sciences in a case where patients claimed the company was negligent in delaying a safer HIV medication, overturning a prior appeals court decision.

The Michigan Supreme Court allowed the state's attorney general to investigate Eli Lilly's insulin pricing practices, rejecting a prior court's decision. The probe alleges the company artificially inflated prices for three insulin products, leading to patient hardships including rationing and health risks.

JPMorgan highlights a sector with 'most durable growth' that has been overlooked for AI, identifying Eli Lilly, AbbVie, and Danaher Corporation as top stock picks in the sector.

A former doctor, using the alias Richard Graydon, evaded detection for two decades while working in the biotech industry. A New Hampshire hospital is suing Eli Lilly over data requirements tied to the 340B drug discount program.

Novo Nordisk is requesting a court to block Eli Lilly's advertisements for Zepbound and Mounjaro, alleging the ads use outdated data and fail to mention newer, higher-dose versions of Wegovy and Ozempic.

Eli Lilly's experimental weight-loss drug, retatrutide, showed participants lost an average of 50 pounds over 18 months in late-stage trials. The medication targets three hormones related to appetite and metabolism and is under FDA review, with a decision possible by 2027. Common side effects included stomach-related issues.

Mosaic Fertilizer and Tampa Port Services agreed to a $103,000 federal penalty for an ammonia release incident. Eli Lilly's experimental obesity drug retatrutide showed no increased heart risk in a safety study. U.S. jobless claims fell to 187,000, the lowest since 1969.

Eli Lilly's obesity drug retatrutide showed significant weight loss in a Phase 3 study but did not reduce cardiovascular risk. The U.S. Medicare program is offering injectable GLP-1 obesity medications like Wegovy, Foundayo, and Zepbound through a trial program for $50 monthly, with high patient demand for injectables despite expectations of pill preference.

Eli Lilly is delaying the FDA approval filing for its next-generation triple-hormone weight loss drug from this year to early 2027. The company had previously indicated it could seek approval as early as 2024.

Eli Lilly will file for approval of its next-generation obesity drug retatrutide in 2027 after achieving positive results in five late-stage trials. The drug is being positioned as a key component of the company's obesity portfolio.

Eli Lilly's retatrutide, a next-generation obesity drug, showed significant weight loss in a Phase 3 study of 2,000 participants with severe obesity and heart disease, but did not demonstrate a statistically significant reduction in cardiovascular risk. The trial was not designed to assess cardiovascular outcomes, and event rates were lower than expected.

Arkansas Attorney General Tim Griffin sued pharmaceutical companies including Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, alleging they conspired to block healthcare providers from accessing discounted drugs under the 340B federal program. The companies are accused of imposing restrictive requirements to limit the use of contract pharmacies, which covered entities rely on to serve underserved communities.

Novo Nordisk sued Eli Lilly for misleading advertising in the US weight-loss drug market, alleging outdated weight-loss comparisons. Novo also previously sued Hims & Hers over a copycat version of Wegovy. The dispute highlights differences in global advertising regulations, as most countries prohibit ads for prescription-only medications.

Pennsylvania Gov. Josh Shapiro announced a $125 million state initiative, Innovate in PA 2.0, to support life sciences startups through funding, clinical trials, and workforce development. The program was unveiled at B+labs in Schuylkill Yards, Philadelphia, where Shapiro highlighted partnerships like Eli Lilly’s biotech incubator and emphasized Pennsylvania’s growing role in biotechnology research and investment.

U.S. LNG exports are projected to nearly double by 2031, contributing $1.4 trillion to the economy. Chatagnier Community Market will open in Prairieville to sell locally produced goods. Novo Nordisk sued Eli Lilly over misleading drug advertising claims.

Novo Nordisk sued Eli Lilly, alleging deceptive advertising claims about its weight-loss drug Zepbound compared to Novo Nordisk's Wegovy. The lawsuit claims Eli Lilly's ads use outdated clinical trials comparing different doses and mislead consumers into believing Zepbound is superior. Eli Lilly has defended its advertising and intends to contest the lawsuit.

Novo Nordisk sued Eli Lilly over claims that its weight-loss medications work better than Novo's, alleging deceptive advertising with outdated trials. The lawsuit, filed in New Jersey, accuses Lilly of comparing high doses of Zepbound to lower doses of Wegovy and Ozempic. Novo seeks a court order to stop the ads and a correction campaign, with a potential preliminary injunction if compliance is not voluntary.

Novo Nordisk is suing Eli Lilly over 'false and materially misleading' advertisements for its weight-loss and anti-diabetes treatments. The Danish pharmaceutical company alleges Eli Lilly is using outdated trial data to compare its highest doses against lower doses of Novo Nordisk's medicines.

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the company of misleading consumers by using outdated clinical trial data to make its drugs appear more effective than Novo's. The dispute centers on allegations of false advertising related to drug efficacy comparisons.

Novo Nordisk is suing Eli Lilly over advertisements comparing GLP-1 medications. The drugmaker claims Lilly’s ads exclude the most up-to-date clinical information about its drugs.

Novo Nordisk is suing Eli Lilly, alleging that its TV and social media advertisements use outdated trial data to mislead consumers about the efficacy of weight loss drugs Zepbound and Mounjaro compared to rival injections.

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the company of running misleading GLP-1 advertisements. The lawsuit seeks to halt these ads and mandate corrective advertising.

Novo Nordisk sued Eli Lilly for allegedly running a deceptive ad campaign using outdated clinical trials to compare higher doses of its drugs Zepbound and Mounjaro with lower doses of Novo's Wegovy and Ozempic. The lawsuit, filed in New Jersey federal court, accuses Lilly of intentionally confusing consumers through misleading advertising.

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley signals growing pharmaceutical industry interest in psychedelic drugs for mental health treatment. The move reflects broader acceptance of this previously stigmatized medication class.

Eli Lilly will acquire a psychedelic drug developer for up to $3.8 billion, focusing on AtaiBeckley’s BPL-003 nasal spray in late-stage trials for treatment-resistant depression. Analysts project annual sales of $1-$2 billion if the drug succeeds. The company aims to leverage psychedelic chemicals for psychiatric treatments, though challenges in placebo-controlled trials and past industry scandals remain.

Eli Lilly is acquiring AtaiBeckley for $2.8 billion to gain access to experimental psychedelic drugs based on DMT and MDMA.

Biogen's experimental Alzheimer's drug diranersen showed slowed cognitive decline in a mid-stage trial, prompting a potential Phase 3 trial. A study highlighted potential frailty risks in older adults using Eli Lilly's Zepbound and Novo Nordisk's Wegovy, urging closer monitoring for seniors.